株式会社グローバルインフォメーション
TEL: 044-952-0102
企業レポート

イーライリリー:製薬企業分析レポート

Eli Lilly Pipeline * Products * Performance * Potential

発行 Espicom Business Intelligence 商品コード 25002
出版日 ページ情報 英文 142 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
イーライリリー:製薬企業分析レポート Eli Lilly Pipeline * Products * Performance * Potential
出版日: 2010年01月31日 ページ情報: 英文 142 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

製薬、医療機器市場に関する調査会社として権威のある情報を提供するEspicom Business Intelligence(本社:英国)では、イーライリリーの業務分析を行った報告書"Eli Lilly - Prospects to 2010"を発行いたしました。

当報告書では、イーライリリーの企業戦略、製品ポートフォリオ、財務実績や、2000年から2010年までの売上データなどを概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • イントロダクション
  • 2005年の財務実績
    • 売上
    • 収益
    • 支出
    • 事業部業績
    • 地域別業績
  • 企業戦略
    • M&A
    • 従業員
  • 製品/R&D概要
    • 主要製品
    • R&D戦略
    • R&Dパイプライン概要
    • 売上予測
  • 結論

製品ポートフォリオ/R&D

  • 神経系
  • 内分泌系疾患
  • 心血管系
  • 抗感染薬
  • その他

付録

  • 財務実績
  • 主な提携
  • インフラ
    • 研究開発施設
    • 生産施設
  • 関連会社/ジョイント・ベンチャー
  • 製品インデックス
目次
Product Code: 125

Abstract

Eli Lilly is a global manufacturer and distributor of pharmaceutical therapies for cancer, cardiovascular diseases, central nervous system ailments, diabetic and endocrine system disorders, and infectious diseases. Lilly' s top selling product is Zyprexa, an antipsychotic for the treatment of schizophrenia, with sales in 2008 of over US$4.6 billion.

Lilly has been in operation for 120 years, in which time it has firmly established itself as a leading pharmaceutical company both domestically in the US and on a global scale. In recent times, Lilly has been consistently placed in the top ten research-based companies in terms of pharmaceutical sales and has developed a competitive product portfolio containing six blockbuster products with sales in excess of US$1 billion.

Between 2003 and 2006, Lilly made signficant introductions to this portfolio, with Byetta, Cialis, Alimta, and Cymbalta all making strong entries to their respective markets. In spite of an incrasingly difficult global pharmaceutical market, Lilly performed extremely well in fiscal 2007. All reportable segments and geographic regions recorded double-digit sales growth, whilst company income also recorded double-digit growth. Lilly' s performance during this fiscal period stands out amongst many of its competitors and places the company in good stead for the short- to medium-term.

Potential to maintain Lilly' s recent strong performance comes from its promising pipeline, which contains a number of novel candidate compounds and several line extensions for major products. Arzoxifene is in late-stage clinical trials and would provide a large boost to Lilly' s endocrine and oncology portfolios, although enzastaurin has recently been found to be unlikely to achieve its primary endpoint of its Phase III trials, presenting a major setback. The development of Arxxant currently remains in doubt as Lilly reviews its options. LY450139 is a landmark product for Lilly, becoming the first putative disease-modifying drug for Alzheimer' s disease that has reached the pipeline for a number of years.

This new strategic analysis report Eli Lilly: Pipeline " Products " Performance " Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Table of Contents

  • Latest Results
  • EXECUTIVE SUMMARY
    • Introduction
    • Company Performance
      • Business Segment Performance
      • Geographic Segment Performance
    • Company Strategy
      • R&D Strategy
      • Mergers, Acquisitions and Divestitures
      • Key Agreements
        • Discontinued Agreements
      • Employees
    • Product Performance Forecasts
    • Pipeline Analysis
      • Discontinued R&D Projects
    • Conclusions
  • THERAPEUTIC AREA FOCUS
  • R&D PIPELINE
  • NEUROSCIENCE
    • Marketed Products
      • Cymbalta/Xeristar
      • Zyprexa
      • Others
    • R&D Projects
      • Arxxant
      • GRC 6211
      • LY2140023
      • LY2624803
      • mGluR3 antagonist
      • mGlu23 prodrug
      • Pruvanserin
      • Semagacestat
      • Solanezumab
    • Growth Forecast
  • ENDOCRINE DISEASES
    • Marketed Products
      • Actos
      • Byetta
      • Evista
      • Forteo/Forteo/Forsteo
      • Humalog
      • Others
    • R&D Projects
      • LY2189265
      • PSN010
      • Teplizumab
      • TT-223
    • Growth Forecast
  • ONCOLOGY
    • Marketed Products
      • Alimta
      • Gemzar
      • R&D Projects
      • Arzoxifene
      • Cixutumumab
      • Enzastaurin
      • IMC-EB10
      • LY2181308
      • LY2469298
      • Necitumumab
      • Ramucirumab
      • Survivin ASO
    • Growth Forecast
  • CARDIOVASCULAR
    • Marketed Products
      • Cialis
      • Effient
      • Others
    • R&D Projects
      • LY518674
    • Growth Forecast
  • OTHERS
    • Marketed Products
    • R&D Projects
      • BAFF antagonist
      • INCB28050
      • Interleukin-17 (IL-17) antibody
      • LY2127399
      • LY307161
      • LY333531
      • OpRA II
  • APPENDIX 1 - FINANCIAL PERFORMANCE
    • Full Year Results 2008
  • APPENDIX 2 - KEY AGREEMENTS
    • Adolor Co
    • Alcon
    • Ambryx Inc
    • Amylin Pharmaceuticals Inc
    • Anthera Pharmaceuticals Inc
    • Applied NeuroSolutions
    • AstraZeneca
    • Biosite Diagnostics Incorporated
    • Boehringer Ingelheim
    • Cardiome Pharma
    • Centocor Inc
    • Covance Inc
    • Cubist Pharmaceuticals Inc
    • Daiichi Sankyo
    • Deciphera Pharmaceuticals LLC
    • Elan Corporation/Amarin Corporation plc
    • Emisphere Technologies Inc
    • Galapagos NV
    • Gastrotech Pharma AS
    • Gene Logic Inc
    • General Electric/GE Global Research/GE Healthcare
    • Glenmark Pharmaceuticals Ltd
    • Hutchison MediPharma Ltd
    • Implicit Bioscience Ltd
    • Incyte Corporation
    • International Diabetes Federation
    • Isis Pharmaceuticals Inc
    • Juvenile Diabetes Research Foundation
    • Kowa Pharmaceuticals America Inc
    • Ligand Pharmaceuticals Inc
    • MacroGenics Inc
    • Medarex Inc
    • Merck KGaA
    • NPIL Research & Development
    • NeuroSearch AS
    • NOXXON Pharma AG
    • PDL BioPharma Inc
    • Phytogenics
    • Prosidion Ltd
    • sanofi-aventis
    • Shionogi
    • Sirna Therapeutics Inc
    • Solvay
    • Takeda
    • TorreyPines Therapeutics
    • Transition Therapeutics Inc
    • TransPharma Medical Ltd
    • United Therapeutics Ltd
    • ViroPharma Incorporated
    • Zydus Cadila Ltd
  • APPENDIX 3 - INFRASTRUCTURE
    • Research And Development Facilities
    • Manufacturing Facilities
  • APPENDIX 4 - KEY SUBSIDIARIES / JOINT VENTURES
    • Subsidiaries
    • Joint Ventures
  • APPENDIX 5 - PRODUCT INDEX

INDEX OF TABLES

  • Principal Operating Results
  • Sales By Business Area
  • Sales By Geographic Area
  • Long-Lived Assets By Geographic Area
  • Recent Product Approvals
  • Major Products, Therapeutic Areas and Sales
  • Major Neuroscience Products, 2008
  • Major Endocrine Disease Products, 2008
  • Major Oncology Products, 2008
  • Major Cardiovascular Products, 2008

INDEX OF CHARTS

  • Sales, Costs and Operating Income
  • R&D Expenditure and Capital Expenditure
  • Sales By Business Area
  • Sales By Geographic Area
  • Sales of Major Products (2003A-2013E)
  • Top Selling Products, 2008
  • Cymbalta Sales (2004A-2013E)
  • Zyprexa Sales (2003A-2012E)
  • Actos Sales (2003A-2013E)
  • Byetta Sales (2005A-2013E)
  • Evista Sales (2003A-2013E)
  • Forteo Sales (2003A-2013E)
  • Humalog Sales (2003A-2013E)
  • Alimta Sales (2004A-2013E)
  • Gemzar Sales (2003A-2013E)
  • Arzoxifene Sales (2010E-2014E)
  • Enzastaurin Sales (2010E-2014E)
  • Cialis Sales (2003A-2013E)
  • Effient Sales (2009E-2013E)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity
Back to Top